Experimed
Cure8 research brief
Why This Matters
Preclinical data suggest sodium phenylbutyrate and suramin may reduce inflammation and oxidative stress in a mouse model of ulcerative colitis, pointing to possible therapeutic mechanisms worth further study.
Who Should Pay Attention
Researchers, translational scientists, and clinicians interested in experimental IBD therapies and inflammatory/epigenetic mechanisms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This report describes preclinical laboratory work (mouse DSS colitis) not human clinical results. The authors measured disease activity, tissue histology, oxidative-stress markers, cytokines, apoptosis proteins, gene expression (STAT1/3, SIRT), and histone modification, and observed improvements with PBA or suramin compared with untreated DSS-exposed mice.
These findings are mechanistic and exploratory: they support further research but do not establish safety or efficacy in people with IBD. Translation to human treatment would require additional preclinical work and well‑designed clinical trials.
Keep In Mind
Findings come from a DSS-induced mouse model and are exploratory. This is not evidence that these drugs are safe or effective in people with IBD; clinical trials would be required.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationExperimed
PublisherIstanbul University
AuthorsPelin Arda Pirincci, Cansu Özal Coşkun, Ecem Fatma Karaman +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 12, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Weissella confusa RY-1 ameliorates DSS-induced colitis by restoring intestinal barrier, modulating gut microbiota, and reprogramming microbial metabolism
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
Extracellular Vesicles Derived from Elaeocarpus braceanus Alleviate DSS-Induced Ulcerative Colitis in Mice Through Multiple Pathways
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
SR9009 regulates macrophage polarization via the NR1D1/NF-κB axis to ameliorate obesity-associated ulcerative colitis
This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.